Sangivamycin 是蛋白激酶 C (PKC) 的有效抑制剂 (Ki = 10 μM)。 Sangivamycin 对多种人类癌症细胞具有抗增殖活性。

Sangivamycin is an effective inhibitor of protein kinase C (PKC, Ki = 10 μM). Sangivamycin exhibits antiproliferative activity against a variety of human cancers.

Sangivamycin (0.3 μM; 0-72 hours) exhibits almost maximal cytocidal for MCF7/ADR or cytostatic for MCF7/WT effects. Sangivamycin activates caspases in MCF7/ADR cells. Upon exposure of MCF7/ADR cells to Sangivamycin (0.3 μM), a vast amount of cleavage of lamin A to a 28-kDa fragment is detected within 48 hours. Sangivamycin has differential antitumor effects in drug-sensitive MCF7/wild type (WT) cells, causing growth arrest, and in multidrug-resistant MCF7/adriamycin-resistant (ADR) human breast carcinoma cells, causing massive apoptotic cell death[2].

18417-89-5

C12H15N5O5

309.28

NSC 65346;BA-90912;桑霉素

DMSO:95 mg/mL (307.17 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years